CRF1Corticotropin-Releasing Factor 1
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
"When this happens, CRF1 tells these cells to release chemical substances that can lead to inflammatory and allergic diseases such as irritable bowel syndrome, asthma, life-threatening food allergies and autoimmune disorders such as lupus."
One group of mice was considered "normal" with CRF1 receptors on their mast cells and the other group had cells that lacked CRF1.
Millan, "The CRF1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized rats," European Journal of Pharmacology, vol.
Interventions that were found to have some beneficial effect in preclinical studies include non-NMDA and NMDA receptor antagonists, mGluR1 and mGluR5 antagonists, agonists for group II mGluR2/3 and group Ill mGluR, including mGluR8, antagonists for CGRP1 and CRF1 receptors, neuropeptide S activating NPS receptors, and inhibitors of ERK and PKA (reviewed in [7]).
Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout.
Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways.
The CRF1 (the alert battalion) requirements were primarily planned and validated by the Cacti of the 2nd Battalion, 35th Infantry Regiment.
For example, the GlaxoSmithKline ( product development pipeline (click on Research & Development, then follow Development) contains numerous new drugs for conditions (and putative mechanisms) like depression and anxiety (CRF1 antagonist), drug dependency (DA3 antagonist), bipolar disorder (sodium channel blocker), sleep disorders (orexin antagonist), and dementia (5-H[T.sub.6] antagonist) (February 2010 download).
Neurocrine Biosciences reported efficacy and safety results from a Phase II trial using Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients experiencing a major depressive episode.
The Phase 2 trial, which involved 150 patients experiencing a major depressive episode, found no benefit for patients treated with the experimental drug, a corticotropin releasing factor (CRF1) receptor antagonist called GSK561679.
Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors.